View in EDS HTML Full Text PDF Full Text

Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study

Saved in:
Bibliographic Details
Title: Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study
Authors: D'Angelo, Salvatore1 (AUTHOR) saldangelo@katamail.com, Tirri, Enrico2 (AUTHOR), Giardino, Angela Maria3 (AUTHOR), De Rosa, Tiziana3 (AUTHOR), Matucci‐Cerinic, Marco4,5 (AUTHOR), Dagna, Lorenzo5 (AUTHOR), Santo, Leonardo6 (AUTHOR), Ciccia, Francesco7 (AUTHOR), Frediani, Bruno8 (AUTHOR), Govoni, Marcello9 (AUTHOR), Pallavicini, Francesca Bobbio10 (AUTHOR), Grembiale, Rosa Daniela11 (AUTHOR), Sedie, Andrea Delle12 (AUTHOR), Mulè, Rita13 (AUTHOR), Cantatore, Francesco Paolo14 (AUTHOR), Foti, Rosario15 (AUTHOR), Gremese, Elisa16 (AUTHOR), Conigliaro, Paola17 (AUTHOR), Salaffi, Fausto18 (AUTHOR), Viapiana, Ombretta19 (AUTHOR)
Source: International Journal of Rheumatic Diseases. Mar2024, Vol. 27 Issue 3, p1-7. 7p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17561841
DOI:10.1111/1756-185X.15091